Conserved HBV and HCV sequences useful for gene silencing

Details for Australian Patent Application No. 2004263832 (hide)

Owner Alnylam Pharmaceuticals, Inc.

Inventors Pachuk, Catherine J.; Satishchandran, C.; Zurawski, Vincent R. Jr.; Mintz, Liat

Agent Pizzeys

Pub. Number AU-B-2004263832

PCT Pub. Number WO2005/014806

Priority 60/478,076 12.06.03 US

Filing date 10 June 2004

Wipo publication date 17 February 2005

Acceptance publication date 1 July 2010

International Classifications

A61K 38/00 (2006.01) Medicinal preparations containing peptides

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

Event Publications

15 December 2005 PCT application entered the National Phase

  PCT publication WO2005/014806 Priority application(s): WO2005/014806

12 March 2009 Assignment before Grant

  Nucleonics, Inc. The application has been assigned to Alnylam Pharmaceuticals, Inc.

1 July 2010 Application Accepted

  Published as AU-B-2004263832

28 October 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004263840-QTL "mapping as-you-go"

2004263830-Double-stranded ribonucleic acid with increased effectiveness in an organism